<p>Foresite Capital Management V LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在 Lyell Immunopharma, Inc. (NASDAQ:LYEL - 免费报告) 的持股减少了 95.0%。该公司在此期间出售了 7,726,395 股后，持有 406,652 股该公司的股票。Lyell Immunopharma 占 Foresite Capital Management V LLC 投资组合的约 4.5%，使其成为第六大持股。Foresite Capital Management V LLC 在最近一个季度末持有的 Lyell Immunopharma 的股份约占 2.63%，价值 3,595,000 美元。</p>
<p>其他几家大型投资者最近也调整了对该公司的持股。Almitas Capital LLC 在第一季度将其在 Lyell Immunopharma 的股份增加了 136.3%。Almitas Capital LLC 目前持有 2,482,606 股该公司的股票，价值 1,336,000 美元，此前在此期间又购买了 1,432,086 股。Nuveen LLC 在第一季度购买了 Lyell Immunopharma 的新股份，价值约 345,000 美元。Acadian Asset Management LLC 在第一季度将其在 Lyell Immunopharma 的持股增加了 204.2%。Acadian Asset Management LLC 目前持有 660,899 股该公司的股票，价值 354,000 美元，此前又购买了 443,614 股。最后，AQR Capital Management LLC 在第一季度将其在 Lyell Immunopharma 的股份增加了 773.5%。AQR Capital Management LLC 目前持有 174,279 股该公司的股票，价值 94,000 美元，此前在上个季度又购买了 154,327 股。目前，66.05% 的股票由机构投资者持有。</p>
<p>获取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>几位股票研究分析师最近对该股票发布了报告。Wall Street Zen 在 9 月 1 日的研究报告中将 Lyell Immunopharma 的股票评级从 “卖出” 上调至 “持有”。HC Wainwright 在周一重申了 “中性” 评级，并将 Lyell Immunopharma 的目标价设定为 20.00 美元（之前为 10.00 美元）。最后，Weiss Ratings 在 10 月 8 日的报告中重申了对 Lyell Immunopharma 的 “卖出（d-）” 评级。一位股票研究分析师对该股票给予了持有评级，另一位则给予了卖出评级。根据 MarketBeat.com 的数据，Lyell Immunopharma 目前的共识评级为 “减持”，共识目标价为 20.00 美元。</p>
<p><strong>查看我们关于 Lyell Immunopharma 的最新报告</strong></p>
<h2>Lyell Immunopharma 价格表现</h2>
<p>NASDAQ:LYEL 的股票在周二开盘价为 22.72 美元。该公司的 50 日移动平均价格为 16.54 美元，200 日移动平均价格为 12.41 美元。Lyell Immunopharma, Inc. 的一年最低价为 7.65 美元，一年最高价为 22.99 美元。该股票的市值为 4.8212 亿美元，市盈率为 -0.99，贝塔值为 -0.07。</p>
<p>Lyell Immunopharma (NASDAQ:LYEL - 获取免费报告) 最近在 11 月 12 日宣布了其季度财报。该公司报告本季度每股收益为（2.13 美元），超出市场共识预期的（2.81 美元）0.68 美元。Lyell Immunopharma 的股本回报率为 -96.68%，净利润率为 -794,292.69%。该公司在本季度的收入为 0.02 万美元，而分析师的预期为 0.01 万美元。分析师预计，Lyell Immunopharma, Inc. 在当前财政年度的每股收益将为 -0.78。</p>
<h2>Lyell Immunopharma 公司简介</h2>
<p>（免费报告）</p>
<p>Lyell Immunopharma, Inc. 是一家临床阶段的细胞治疗公司，开发针对实体肿瘤患者的 T 细胞重编程技术。该公司利用体外基因重编程技术（如 c Jun 过表达和 NR4A3 基因敲除）开发疗法，以赋予 T 细胞抵抗疲劳的能力；以及体外表观遗传重编程技术，包括 Epi R 以生成具有持久干性的人群 T 细胞，以及 Stim R，一种专有合成细胞仿生物。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Lyell Immunopharma</li>
<li>如何计算投资回报率 (ROI)</li>
<li>D-Wave：是时候买入了吗？还是下跌才刚刚开始？</li>
<li>金融服务股票投资</li>
<li>Hims、Block 和 NRG 刚刚启动了大规模股票回购</li>
<li>英国市场假期有哪些？如何投资和交易</li>
<li>零售收益汇总：沃尔玛表现优异，塔吉特在第三季度下滑</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Lyell Immunopharma 吗？</h2>
<p>在考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Lyell Immunopharma 并不在名单上。</p>
<p>虽然 Lyell Immunopharma 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

LYEL

<p>Foresite Capital Management V LLC 在第二季度根据其最新的 SEC 文件减少了对 Lyell Immunopharma, Inc.的持股，降幅达到 95%。该公司目前持有 406,652 股，较之前的 810 万股大幅减少，使 Lyell 成为其第六大持股。机构投资者持有 Lyell 股票的 66.05%。分析师对该股票的评级意见不一，普遍评级为 “减持”，目标价格为 20.00 美元。Lyell 的股票开盘价为 22.72 美元，市值为 4.8212 亿美元</p>

<p>Foresite Capital Management V LLC trimmed its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 95.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 406,652 shares of the company's stock after selling 7,726,395 shares during the period. Lyell Immunopharma comprises about 4.5% of Foresite Capital Management V LLC's investment portfolio, making the stock its 6th largest holding. Foresite Capital Management V LLC owned about 2.63% of Lyell Immunopharma worth $3,595,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Foresite Capital Management V LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在 Lyell Immunopharma, Inc. (NASDAQ:LYEL - 免费报告) 的持股减少了 95.0%。该公司在此期间出售了 7,726,395 股后，持有 406,652 股该公司的股票。Lyell Immunopharma 占 Foresite Capital Management V LLC 投资组合的约 4.5%，使其成为第六大持股。Foresite Capital Management V LLC 在最近一个季度末持有的 Lyell Immunopharma 的股份约占 2.63%，价值 3,595,000 美元。</p>
</div><p>Several other large investors also recently modified their holdings of the business. Almitas Capital LLC raised its position in shares of Lyell Immunopharma by 136.3% during the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock worth $1,336,000 after purchasing an additional 1,432,086 shares during the period. Nuveen LLC bought a new stake in Lyell Immunopharma during the 1st quarter worth approximately $345,000. Acadian Asset Management LLC raised its holdings in Lyell Immunopharma by 204.2% during the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock worth $354,000 after buying an additional 443,614 shares during the period. Finally, AQR Capital Management LLC lifted its stake in Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock valued at $94,000 after buying an additional 154,327 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也调整了对该公司的持股。Almitas Capital LLC 在第一季度将其在 Lyell Immunopharma 的股份增加了 136.3%。Almitas Capital LLC 目前持有 2,482,606 股该公司的股票，价值 1,336,000 美元，此前在此期间又购买了 1,432,086 股。Nuveen LLC 在第一季度购买了 Lyell Immunopharma 的新股份，价值约 345,000 美元。Acadian Asset Management LLC 在第一季度将其在 Lyell Immunopharma 的持股增加了 204.2%。Acadian Asset Management LLC 目前持有 660,899 股该公司的股票，价值 354,000 美元，此前又购买了 443,614 股。最后，AQR Capital Management LLC 在第一季度将其在 Lyell Immunopharma 的股份增加了 773.5%。AQR Capital Management LLC 目前持有 174,279 股该公司的股票，价值 94,000 美元，此前在上个季度又购买了 154,327 股。目前，66.05% 的股票由机构投资者持有。</p>
</div><p>Get <strong>Lyell Immunopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Lyell Immunopharma from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Monday, September 1st. HC Wainwright reiterated a &#34;neutral&#34; rating and set a $20.00 target price (up previously from $10.00) on shares of Lyell Immunopharma in a report on Monday. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Lyell Immunopharma in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Lyell Immunopharma presently has a consensus rating of &#34;Reduce&#34; and a consensus price target of $20.00.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该股票发布了报告。Wall Street Zen 在 9 月 1 日的研究报告中将 Lyell Immunopharma 的股票评级从 “卖出” 上调至 “持有”。HC Wainwright 在周一重申了 “中性” 评级，并将 Lyell Immunopharma 的目标价设定为 20.00 美元（之前为 10.00 美元）。最后，Weiss Ratings 在 10 月 8 日的报告中重申了对 Lyell Immunopharma 的 “卖出（d-）” 评级。一位股票研究分析师对该股票给予了持有评级，另一位则给予了卖出评级。根据 MarketBeat.com 的数据，Lyell Immunopharma 目前的共识评级为 “减持”，共识目标价为 20.00 美元。</p>
</div><p><strong>View Our Latest Report on Lyell Immunopharma</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Lyell Immunopharma 的最新报告</strong></p>
</div><h2>Lyell Immunopharma Price Performance</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 价格表现</h2>
</div><p>Shares of NASDAQ:LYEL opened at $22.72 on Tuesday. The company's 50-day moving average price is $16.54 and its two-hundred day moving average price is $12.41. Lyell Immunopharma, Inc. has a one year low of $7.65 and a one year high of $22.99. The stock has a market capitalization of $482.12 million, a PE ratio of -0.99 and a beta of -0.07.</p>
<div class="lb-trans"><p>NASDAQ:LYEL 的股票在周二开盘价为 22.72 美元。该公司的 50 日移动平均价格为 16.54 美元，200 日移动平均价格为 12.41 美元。Lyell Immunopharma, Inc. 的一年最低价为 7.65 美元，一年最高价为 22.99 美元。该股票的市值为 4.8212 亿美元，市盈率为 -0.99，贝塔值为 -0.07。</p>
</div><p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.81) by $0.68. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%.The company had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.01 million. On average, analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Lyell Immunopharma (NASDAQ:LYEL - 获取免费报告) 最近在 11 月 12 日宣布了其季度财报。该公司报告本季度每股收益为（2.13 美元），超出市场共识预期的（2.81 美元）0.68 美元。Lyell Immunopharma 的股本回报率为 -96.68%，净利润率为 -794,292.69%。该公司在本季度的收入为 0.02 万美元，而分析师的预期为 0.01 万美元。分析师预计，Lyell Immunopharma, Inc. 在当前财政年度的每股收益将为 -0.78。</p>
</div><h2>Lyell Immunopharma Company Profile</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.</p>
<div class="lb-trans"><p>Lyell Immunopharma, Inc. 是一家临床阶段的细胞治疗公司，开发针对实体肿瘤患者的 T 细胞重编程技术。该公司利用体外基因重编程技术（如 c Jun 过表达和 NR4A3 基因敲除）开发疗法，以赋予 T 细胞抵抗疲劳的能力；以及体外表观遗传重编程技术，包括 Epi R 以生成具有持久干性的人群 T 细胞，以及 Stim R，一种专有合成细胞仿生物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Lyell Immunopharma</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?</li>
<li>Financial Services Stocks Investing</li>
<li>Hims, Block, and NRG Just Launched Huge Stock Buybacks</li>
<li>What Are the U.K. Market Holidays? How to Invest and Trade</li>
<li>Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Lyell Immunopharma</li>
<li>如何计算投资回报率 (ROI)</li>
<li>D-Wave：是时候买入了吗？还是下跌才刚刚开始？</li>
<li>金融服务股票投资</li>
<li>Hims、Block 和 NRG 刚刚启动了大规模股票回购</li>
<li>英国市场假期有哪些？如何投资和交易</li>
<li>零售收益汇总：沃尔玛表现优异，塔吉特在第三季度下滑</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=LYEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lyell Immunopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Lyell Immunopharma 吗？</h2>
</div><p>Before you consider Lyell Immunopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Lyell Immunopharma 并不在名单上。</p>
</div><p>While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lyell Immunopharma 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Foresite Capital Management V LLC 减持了 Lyell Immunopharma, Inc. $LYEL 的股票